CINECA IRIS Institutional Research Information System

CIAMPI, RAFFAELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.483
EU - Europa 4.486
AS - Asia 3.026
SA - Sud America 446
AF - Africa 192
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 14.643
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.306
IT - Italia 1.840
CN - Cina 922
SG - Singapore 876
DE - Germania 875
HK - Hong Kong 641
SE - Svezia 597
BR - Brasile 386
GB - Regno Unito 244
BG - Bulgaria 204
AT - Austria 171
CA - Canada 145
TR - Turchia 129
RU - Federazione Russa 127
VN - Vietnam 124
CI - Costa d'Avorio 105
IN - India 102
FI - Finlandia 97
FR - Francia 72
UA - Ucraina 58
NL - Olanda 54
KR - Corea 49
SN - Senegal 45
JP - Giappone 35
BD - Bangladesh 27
PL - Polonia 25
CH - Svizzera 22
MX - Messico 20
IQ - Iraq 18
BE - Belgio 17
ZA - Sudafrica 16
EE - Estonia 15
AR - Argentina 14
EC - Ecuador 13
ES - Italia 13
ID - Indonesia 12
MA - Marocco 11
PK - Pakistan 11
SA - Arabia Saudita 11
TW - Taiwan 9
VE - Venezuela 9
CZ - Repubblica Ceca 8
IR - Iran 8
UZ - Uzbekistan 8
CO - Colombia 7
IL - Israele 6
PE - Perù 6
RO - Romania 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
GR - Grecia 5
JO - Giordania 5
LT - Lituania 5
AL - Albania 4
AU - Australia 4
BY - Bielorussia 4
KE - Kenya 4
MY - Malesia 4
RS - Serbia 4
UY - Uruguay 4
CL - Cile 3
DO - Repubblica Dominicana 3
EU - Europa 3
HU - Ungheria 3
NG - Nigeria 3
NP - Nepal 3
NZ - Nuova Zelanda 3
PH - Filippine 3
PT - Portogallo 3
PY - Paraguay 3
DK - Danimarca 2
DZ - Algeria 2
EG - Egitto 2
GT - Guatemala 2
IE - Irlanda 2
JM - Giamaica 2
LK - Sri Lanka 2
MK - Macedonia 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BO - Bolivia 1
BZ - Belize 1
GD - Grenada 1
GE - Georgia 1
HR - Croazia 1
IS - Islanda 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MM - Myanmar 1
MT - Malta 1
NI - Nicaragua 1
NO - Norvegia 1
QA - Qatar 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 14.640
Salva come PNG Salva come JPEG
Città #
Ashburn 718
Dallas 647
Hong Kong 631
Woodbridge 593
Singapore 466
Fairfield 464
Chandler 395
Ann Arbor 393
Santa Clara 380
Houston 349
Milan 293
Shanghai 211
Beijing 206
Sofia 203
Seattle 171
New York 166
Wilmington 166
Vienna 163
Cambridge 151
Ottawa 110
Los Angeles 106
Abidjan 105
Boardman 103
Pisa 91
Princeton 91
Rome 89
Florence 77
Lawrence 76
Munich 69
Medford 64
Serra 63
Izmir 61
Jacksonville 58
Frankfurt am Main 57
Dearborn 54
Hefei 54
Nanjing 52
London 51
São Paulo 48
Dakar 45
Des Moines 45
Seoul 45
Istanbul 44
Naples 44
Redondo Beach 44
Bremen 36
Bologna 32
San Diego 32
Buffalo 29
Düsseldorf 25
Dong Ket 24
Tokyo 24
Helsinki 21
Ho Chi Minh City 21
Redmond 21
Redwood City 21
Boulder 20
Lancaster 20
Nanchang 20
Cascina 17
Fuzhou 17
Turin 17
Brussels 16
Bern 15
Chicago 15
Turku 15
Verona 15
Bengaluru 14
Boston 14
Brooklyn 14
Genoa 14
Guangzhou 14
Hangzhou 14
Hanoi 14
Ogden 14
Palermo 14
Rio de Janeiro 14
Parma 13
Changsha 12
Council Bluffs 12
Johannesburg 12
Tianjin 12
Toronto 12
Jaboatão 11
Jüchen 11
Orem 11
Poplar 11
Warsaw 11
Washington 11
Atlanta 10
Baghdad 10
Belo Horizonte 10
Columbus 10
Denver 10
Jiaxing 10
Lucca 10
Porto Alegre 10
Salerno 10
Trieste 10
Wuhan 10
Totale 9.374
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 1.089
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 323
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 270
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 242
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 230
LOW PREVALENCE OF THE SOMATIC M918T RET MUTATION IN MICRO-MEDULLARY THYROID CANCER. 219
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 215
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 214
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 213
Targeted Therapy in Thyroid Cancer: State of the Art 210
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 207
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 206
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 203
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 200
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 192
BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer 190
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 188
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 187
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 183
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 182
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 179
Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma 178
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer 174
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 174
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 172
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 169
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 168
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 163
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 162
Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors 161
null 160
KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease 159
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 158
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 158
null 157
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 153
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 153
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 152
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 151
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 151
Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas 149
null 146
BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization 144
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 143
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 140
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 138
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases 136
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 133
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 133
Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients 132
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 132
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series 131
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 130
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 129
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 129
NIS mRNA and protein expression in thyroid and non thyroid carcinoma 127
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RAR{beta} mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 123
Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid 123
Alterations of the BRAF gene in thyroid tumors 123
null 122
WHOLE EXOME SEQUENCING OF MEDULLARY THYROID CARCINOMA CASES IDENTIFIES 86 VARIATIONS IN GENES POSSIBLY INVOLVED IN TUMORAL TRANSFORMATION 121
Studi in vitro del trattamento con acido retinoico di linee cellulari di carcinoma tiroideo umano anaplastico, scarsamente differenziato, follicolare e midollare 118
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation 116
All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes 115
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 114
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas 113
Molecular classification of papillary thyroid carcinoma: Distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis 111
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 111
Ret mutated C-cells proliferate more rapidly than non-mutated neoplastic cells 111
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 110
HOOK3-RET: A novel type of RET/PTC rearrangement in papillary thyroid carcinoma 109
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 108
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma 107
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 105
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer 104
Minireview: RET/PTC rearrangements and braf mutations in thyroid tumorigenesis 100
null 99
Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature 96
Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: Effects of the detection methods and genetic heterogeneity 96
NF1 Gene Inactivation Acts as Tumor Driver in RET/RAS Negative Medullary Thyroid Carcinomas 93
Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance 92
Genetic heterogeneity of Medullary Thyroid Carcinoma 91
The prognostic role of chromosomal gains and loss in sporadic medullary thyroid carcinoma 90
Correction: Circulating miR‑26b‑5p and miR‑451a as diagnostic biomarkers in medullary thyroid carcinoma patients 89
The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma 88
Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to γ-radiation: A model of carcinogenic chromosomal rearrangement induced by ionizing radiation 88
Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer 88
KIF5B/RET rearrangement in diffuse sclerosing variant of papillary thyroid cancer (DSV-PTC) 87
SIMULTANEOUS MEDULLARY AND PAPILLARY THYROID CARCINOMAS SHOW INDEPENDENT GENETIC ORIGIN 85
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs 83
Whole Exome Sequencing of Medullary Thyroid Carcinomas did not identify oncogenic drivers alternative to RET and RAS genes 83
null 75
Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value 74
BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review 73
null 70
Ret Oncogene and Thyroid Carcinoma 68
MULTIFOCALITY AND BILATERALITY IN MEDULLARY THYROID CANCER: BASIS FOR A PROOF-OF-CONCEPT SAFETY OF LOBECTOMY 66
BRAF(V600E) mutations are correlated with a lower expression of both NIS and TPO mRNA expression in papillary thyroid cancer (PTC) 65
null 58
null 51
Totale 14.799
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.357
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.357
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021414 0 0 0 0 0 37 75 61 57 59 34 91
2021/20221.068 38 58 21 75 211 131 36 47 55 49 78 269
2022/20231.752 208 250 141 137 144 189 62 125 312 37 108 39
2023/20241.390 158 130 126 110 168 203 118 79 63 39 67 129
2024/20253.291 66 140 63 185 345 298 269 207 330 405 374 609
2025/20262.412 270 594 530 369 400 249 0 0 0 0 0 0
Totale 14.855